Company: ZVRA
Filing Date: 2025-03-31
Form Type: DEFA14A
Source: 0001193125-25-068941
Chunk: 2

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-03-31
Form: DEFA14A
Chunk 2
---
. We are thrilled with our progress,
which positioned Zevra to deliver record net product revenue during the fourth quarter of 2024. As highlighted in our fourth quarter and fiscal year 2024 results, we have a focused plan and a cash runway extending into 2029, without including the
anticipated proceeds from the recent sale of the Priority Review Voucher (PRV), received as a result of FDA approval of MIPLYFFA, for $150 million. This
non-dilutive capital adds significant strength to execute on our strategic priorities, with our immediate focus on executing the commercial launches of MIPLYFFA and OLPRUVA, investments in celiprolol and our other development programs, and building our corporate foundation while we earn the right to make disciplined growth investments in the future.

Over the past several months, we have actively engaged with Mr. Mangless in an attempt
to avoid a costly proxy contest that could distract from our continued strong execution. Given his relatively small ownership of the Company and already having three of his nominees elected to the Board in 2023, Mr. Mangless appears intent on
trying to secure control of the Board to advance his interests, to the detriment of Zevra and its stockholders. We take feedback from our stockholders seriously, and have significant stockholder representation on the Board.

Given our continued momentum, we believe that delivering on our strategic plan is the best path forward. As demonstrated by our outperformance
over the past year compared to peers and the broader market, we are confident that we have the Board and management team in place to execute on our financial and operational goals.”

Zevra’s preliminary proxy materials can be found on the SEC’s website at www.sec.gov. Once finalized, the Company’s definitive proxy materials
will be mailed to all stockholders eligible to vote at the 2025 Annual Meeting. Stockholders may also receive materials, in the mail or otherwise, from Mr. Mangless. The Zevra Board recommends that stockholders discard any proxy materials from
Mr. Mangless and vote using the WHITEproxy card they will receive as part of the definitive proxy materials that will be delivered by the Company.

About Zevra Therapeutics, Inc.

Zevra Therapeutics, Inc.
is a commercial-stage company combining science, data, and patient needs to create transformational therapies for rare diseases with limited or no treatment options. Our mission is to bring life-changing therapeutics to people living with rare
diseases. With unique, data-driven